Cost-effectiveness analysis of Chinese patent medicines for the treatment of postmenopausal osteoporosis in China.

ABSTRACT:

Introduction

Evidence indicates that Chinese patent medicines can significantly increase bone mass in patients with osteoporosis and alleviate symptoms associated with low bone density. Although the therapeutic effects of these two drugs have been compared both directly and indirectly, no economic-related studies currently exist. Therefore, this study aims to assess the cost-effectiveness of Xianling Gubao Capsules compared to Jintiange Capsules and non-treatment for postmenopausal osteoporosis from the perspective of Chinese healthcare providers.

Methods

A Markov microsimulation model was employed to estimate the cost-effectiveness of the Xianling Gubao capsule and the Jintiange capsule in a hypothetical cohort of postmenopausal osteoporotic women aged 55 to 74 years with n

SUBMITTER: Wang C 

PROVIDER: S-EPMC12446330 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature